{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06007651",
            "orgStudyIdInfo": {
                "id": "18769"
            },
            "secondaryIdInfos": [
                {
                    "id": "J4N-MC-YFAA",
                    "type": "OTHER",
                    "domain": "Eli Lilly and Company"
                }
            ],
            "organization": {
                "fullName": "Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)",
            "officialTitle": "A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of LY3885125 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With NAFLD",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "a-study-of-in-participants-with-dyslipidemia-or-non-alcoholic-fatty-liver-disease-nafld"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-18",
            "studyFirstSubmitQcDate": "2023-08-18",
            "studyFirstPostDateStruct": {
                "date": "2023-08-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eli Lilly and Company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests will be performed to check how much LY3885125 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThe study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a total of approximately 111 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Dyslipidemias",
                "Non-Alcoholic Fatty Liver Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 112,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LY3885125 (Part A)",
                    "type": "EXPERIMENTAL",
                    "description": "Single ascending doses of LY3885125 administered subcutaneously (SC)",
                    "interventionNames": [
                        "Drug: LY3885125"
                    ]
                },
                {
                    "label": "Placebo (Part A)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered SC",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "LY3885125 (Part B)",
                    "type": "EXPERIMENTAL",
                    "description": "Repeat doses of LY3885125 administered SC",
                    "interventionNames": [
                        "Drug: LY3885125"
                    ]
                },
                {
                    "label": "Placebo (Part B)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered SC",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY3885125",
                    "description": "Administered SC",
                    "armGroupLabels": [
                        "LY3885125 (Part A)",
                        "LY3885125 (Part B)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Administered SC",
                    "armGroupLabels": [
                        "Placebo (Part A)",
                        "Placebo (Part B)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration",
                    "description": "Part A: A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module",
                    "timeFrame": "Baseline up to 49 weeks (Part A)"
                },
                {
                    "measure": "Part B: Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration",
                    "description": "Part B: A summary of SAEs and other non-serious AEs, regardless of causality, will be reported in the Reported Adverse Events module",
                    "timeFrame": "Baseline up to 62 weeks (Part B)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A & B: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3885125",
                    "description": "Part A \\& B: PK: AUC of LY3885125",
                    "timeFrame": "Baseline up to 49 weeks (Part A) and Baseline up to 62 weeks (Part B)"
                },
                {
                    "measure": "Part A & B: PK: Maximum Observed Plasma Concentration (Cmax) of LY3885125",
                    "description": "Part A \\& B: PK: Cmax of LY3885125",
                    "timeFrame": "Baseline up to 49 weeks (Part A) and Baseline up to 62 weeks (Part B)"
                },
                {
                    "measure": "Part A & B: PK: Time of Maximum Observed Concentration (Tmax) of LY3885125",
                    "description": "Part A \\& B: PK: Tmax of LY3885125",
                    "timeFrame": "Baseline up to 49 weeks (Part A) and Baseline up to 62 weeks (Part B)"
                },
                {
                    "measure": "Part A & B: Pharmacodynamics (PD): Change From Baseline in Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9)",
                    "description": "Part A \\& B: PD: Change From Baseline in PCSK9",
                    "timeFrame": "Baseline up to 49 weeks (Part A) and Baseline up to 62 weeks (Part B)"
                },
                {
                    "measure": "Part A & B: PD: Change From Baseline in apolipoprotein B (ApoB)",
                    "description": "Part A \\& B: PD: Change From Baseline in ApoB",
                    "timeFrame": "Baseline up to 49 weeks (Part A) and Baseline up to 62 weeks (Part B)"
                },
                {
                    "measure": "Part B only: PD: Change of Liver Fat Content From Baseline by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)",
                    "description": "Part B only: PD: Change of Liver Fat Content From Baseline by MRI-PDFF",
                    "timeFrame": "Baseline up to 62 weeks (Part B)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nParts A \\& B\n\n* Males, or females of not of childbearing potential,\n* On a stable diet for the 3 months prior to randomization and willing to continue the same stable diet during the study.\n\nPart A\n\n* Dyslipidemia with the following fasted blood levels at screening: 150 mg/dL \u2264 triglycerides \\<500 mg/dL, AND LDL-cholesterol \u2265100 mg/dL,\n* Body mass index (BMI) in range of 18.5 to 45.0 kg/m2. Part B\n* NAFLD with liver fat content \u22658% as determined by magnetic resonance imaging proton density fat fraction (MRI-PDFF),\n* BMI in range of 27 to 45.0 kg/m2\n\nExclusion Criteria:\n\nParts A \\& B\n\n* History or presence of medical illness including, but not limited to, any cardiovascular, thromboembolism or bleeding disorder, hepatic, respiratory, hematological, endocrine, immune, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the Investigator, indicate a medical problem that would preclude study participation,\n* Uncontrolled hypertension with a resting blood pressure \u2265 160 mmHg systolic or \u2265 100 mmHg diastolic at visit 1,\n* Alanine transaminase (ALT) or aspartate aminotransferase (AST) \\>3.0 \u00d7 ULN for the reference range,\n* Alkaline phosphatase (ALP) \\>1.5 \u00d7 ULN for the reference range,\n* Total bilirubin (TBL) \\>1.5 \u00d7 ULN for the reference range,\n* Taken drugs associated with hepatic steatosis (e.g., amiodarone, valproic acid, methotrexate, tamoxifen) for more than 2 weeks in the 3 months prior to screening visit,\n* Type 1 diabetes mellitus (T1DM) or any other type of diabetes mellitus other than T2DM,\n* Poorly controlled T2DM with glycated hemoglobin (HbA1c) of \\>9.0%,\n* Treatment with GLP-1 RA and GIP/GLP-1 RA and approved or experimental agents that target PCSK9 within 9 months prior to screening visit.\n\nPart B\n\n* Evidence of other forms of chronic liver disease,\n* Initiated treatment with, or changed dose of, medications that may cause significant weight gain or weight loss, within 3 months prior to the screening visit,\n* Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening visit",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "1-317-615-4559",
                    "email": "ClinicalTrials.gov@Lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
                    "affiliation": "Eli Lilly and Company",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Worldwide Clinical Trials, Early Phase Services LLC",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78217",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "210-635-1500"
                        },
                        {
                            "name": "Alan Hand, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                },
                {
                    "id": "D000050171",
                    "term": "Dyslipidemias"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000052439",
                    "term": "Lipid Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Non-alcoholic Fatty Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26181",
                    "name": "Dyslipidemias",
                    "asFound": "Dyslipidemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27029",
                    "name": "Lipid Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Fatty Liver",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}